You are viewing a preview of...

Stabilised RNA Therapeutics

Method to stabilise RNA-based therapeutics for improved storage characteristics and logistics


The CoVid pandemic has seen the rapid evolution and development of messenger ribose nucleic acid (mRNA) based vaccination therapies. It is likely that the use of mRNA based vaccinations and therapeutics (BioNTech is developing RNA-based therapies for cancer etc) will become a much-used technology in the future. A key problem with mRNA based vaccines is that mRNA is rapidly degraded and thus must be kept at very low temperatures of c. - 80 ˚C, requiring specialist freezers such as found in universities or hospitals (normal freezers are c. 18 ˚C). This means that delivery has to be centralised at such facilities in developed economies and is likely to be completely unfeasible in emerging economies. An immediate concern for those

Log in or create a free account to continue reading